Andy Hu

Andy Hu is a physician-turned-dealmaker who serves as Chief Business Officer of Augustine Therapeutics, a Leuven and Cambridge biotech advancing next-generation selective HDAC6 inhibitors for neuromuscular, neurodegenerative, and cardio-metabolic diseases. He joined permanently in April 2025 after a stint as advisor, fresh off serving as CBO of Arkuda Therapeutics through its acquisition by Johnson & Johnson. Trained as an MD at Baylor with an MBA from Rice and an undergraduate degree from Harvard, Hu has built a career steering life sciences companies through IPOs, partnerships, and acquisitions - from Dimension Therapeutics to Ultragenyx, plus stints in investment banking at Leerink Partners and consulting at Strategic Decisions Group.